The Medicines Co (The Medicines Co) Change In Inventory : $0.86 Mil (TTM As of Sep. 2019)

View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Change In Inventory?

The Medicines Co's change in inventory for the quarter that ended in Sep. 2019 was $0.00 Mil. It means The Medicines Co's inventory stayed the same from Jun. 2019 to Sep. 2019 .

The Medicines Co's change in inventory for the fiscal year that ended in Dec. 2018 was $2.20 Mil. It means The Medicines Co's inventory declined by $2.20 Mil from Dec. 2017 to Dec. 2018 .

The Medicines Co's Total Inventories for the quarter that ended in Sep. 2019 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

The Medicines Co Change In Inventory Historical Data

The historical data trend for The Medicines Co's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Change In Inventory Chart

The Medicines Co Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Inventory

Get a 7-Day Free Trial

5.63

-69.32

-15.65

6.51

2.20

The Medicines Co Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Change In Inventory	Get a 7-Day Free Trial															-0.06	-	-0.14	1.00	-

The Medicines Co Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.86 Mil.

The Medicines Co (NAS:MDCO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

The Medicines Co's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

The Medicines Co's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

The Medicines Co's Inventory to Revenue for the quarter that ended in Sep. 2019 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

The Medicines Co Change In Inventory Related Terms

Thank you for viewing the detailed overview of The Medicines Co's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

The Medicines Co (The Medicines Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Change In Inventory

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.themedicinescompany.com

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard	officer: Chief Development Officer	8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox	officer: EVP & Chief Corp. Dev. Officer	CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman	director, officer: Executive Chairman	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler	director
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta	director	THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley	officer: President and COO	152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio	director, officer: President & CFO	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn	10 percent owner, other: Possible Members of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Members of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010